Inventiva Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Inventiva S.A.

Country	France
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	118
CEO	Frederic Cren

Contact Details

Address: 50 rue de Dijon Daix, 21121 France
Phone	33 3 80 44 75 00
Website	inventivapharma.com

Stock Details

Ticker Symbol	IVA
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0013233012
SIC Code	2836

Key Executives

Name	Position
Dr. Pierre Broqua Ph.D.	Co-Founder, Chief Scientific Officer and Deputy Chief Executive Officer
Frederic Cren	Co-Founder, Chief Executive Officer and Director
Jean Volatier	Deputy GM and Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.	Chief Operating Officer
Eric Duranson L.L.M.	General Counsel
Nathalie Harroy	Head of Human Resources
Dr. Kristina Meyer Ph.D.	Executive Vice President and Business Development and Alliance Management
Dr. Michael Cooreman M.D., Ph.D.	Chief Medical Officer
Pascaline Clerc Ph.D.	Executive Vice President of Strategy and Corporate Affairs